Maria Blasco

Background

Maria Blasco is Director of the Spanish National Cancer Research Centre (CNIO) in Madrid and head of its Telomeres and Telomerase Group. She trained with Carol Greider (2009 Nobel laureate for telomere biology) at Cold Spring Harbor and is among the leading telomere researchers worldwide.

Key contributions

Telomerase-knockout mouse models

Generated the first telomerase-deficient (TERT and TERC knockout) mouse lines, which she used to dissect the role of telomeres in:

• Tissue regeneration and stem-cell maintenance.
• Cancer (cells need to reactivate telomerase to escape replicative senescence; absence prevents cancer but produces premature aging).
• The accelerated-aging phenotype of late-generation knockouts.

AAV-TERT gene therapy

Bernardes de Jesus et al. 2012 demonstrated that AAV-delivered TERT in adult and old mice extends median lifespan ~24% with no detectable increase in cancer incidence. This was a striking proof-of-concept for therapeutic telomerase activation in mammals.

Telomere measurement

Her lab has developed methods including high-throughput quantitative-FISH telomere measurement that have been adopted as research-grade telomere-length tools, including for cancer-prognostic applications.

Stem-cell biology

Showed how short telomeres compromise stem-cell function across tissues, linking telomere attrition to broader stem-cell exhaustion.

Influence

Blasco’s lab supplies much of the mechanistic and proof-of-concept work that motivates ongoing telomerase-activation strategies. She has been a consistent voice for the realistic but bounded promise of telomere- focused interventions: real biology, real translational potential, but cancer trade-offs must be addressed carefully.

Affiliations & disclosures

Director of CNIO. Co-founder of Life Length, a Spanish telomere-length diagnostic company. Frequent speaker at major geroscience meetings.

Related entries

Telomere attrition, Telomerase, Telomere length, TERT gene, Hayflick limit, Stem cell exhaustion.